Recurring concern
Unreliable metabolic monitoring for patients taking antipsychotic medication
First reported 2 Dec 2014•Latest report 9 Jul 2015
What this concern includes
Includes failures of controls specifically dedicated to metabolic monitoring for patients taking antipsychotic medication, including defining required tests and frequency, arranging or completing testing, following up refused or missed tests, reviewing results and escalating abnormal or unresolved monitoring.
Not included
- Excludes monitoring of medicines or clinical conditions unrelated to antipsychotic medication and its metabolic risks.
- Excludes generic medication review, prescribing, adherence or discharge failures unless they directly concern metabolic monitoring for antipsychotic treatment.
- Excludes failures limited to monitoring a different antipsychotic safety domain, such as QTc or blood-level monitoring, unless the assertion also concerns metabolic monitoring.
- Excludes failures to act on an abnormal metabolic result when the monitoring process itself was completed reliably.
- Reports
- 3
- Individual concerns
- 4
- Date range
- 2014–2015
- Stated actions
- 4
Distinct published reports
A report can raise multiple concerns
First to latest report issue date
Described in published responses
Reports over time
Reports over time
Reports about this concern issued each year.
* 2026 is projected from reports observed to 7 Sep 2026.
Most frequent recipients
Most frequent recipients
Reports about this concern sent to each recipient.
Concerns and responses across reports
Only concerns grouped under this recurring concern are included. Select any concern, action or position to view the source wording.
-
Concerns raised2
Failure to provide appropriate care plans addressing the risks of refused urine and blood glucose testing
Failure to follow up refused glucose and urine testing for patients on antipsychotics
This report raised 3 other concerns. They are not shown here because they do not form part of this recurring concern.
Responses linked to these concernsEach statement is shown once, even when linked to more than one concern.
Respondent positions A position is what a respondent says about the concern when they do not describe a specific action.1
-
Position
Testing patients who refuse blood or urine samples is constrained by the practical difficulty and unpleasantness of restraint.
Stated by South London and Maudsley NHS Foundation Trust
-
Concerns raised1
Failure to perform routine blood sugar testing during long-term Clozapine treatment
Responses linked to these concernsEach statement is shown once, even when linked to more than one concern.
Actions described in response An action is something a respondent says it has done, is doing, or plans to do in response to the concern raised.1
-
Action
Share the coroner’s report with NHS England.
Stated by Department of Health and Social Care
-
Concerns raised1
Lack of mandatory and regular glucose testing for people on antipsychotic medication
Responses linked to these concernsEach statement is shown once, even when linked to more than one concern.
Actions described in response An action is something a respondent says it has done, is doing, or plans to do in response to the concern raised.3
-
Action
Update the physical healthcare policy to define staff responsibilities and reference Maudsley guidance for patients prescribed Clozapine.
Stated by South London and Maudsley NHS Foundation Trust -
Action
Audit compliance with physical-health monitoring recommendations and provide feedback to clinical services.
Stated by South London and Maudsley NHS Foundation Trust -
Action
Review Clozapine clinics across four boroughs to assess operations, resources, responsibilities and functions, define core functions and standards, and clarify management and reporting structures.
Stated by South London and Maudsley NHS Foundation Trust
Data last updated 7 September 2026